76 related articles for article (PubMed ID: 16648492)
1. Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series.
Bardia A; Loprinzi CL; Goetz MP
J Clin Oncol; 2006 May; 24(13):e18-9. PubMed ID: 16648492
[No Abstract] [Full Text] [Related]
2. Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study.
Lambert-Falls R; Modugno S
Clin Breast Cancer; 2007 Aug; 7(9):697-704. PubMed ID: 17919350
[TBL] [Abstract][Full Text] [Related]
3. A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer.
Margolin S; Bengtsson NO; Carlsson L; Edlund P; Hellstrøm M; Karlsson P; Lidbrink E; Linderholm B; Lindman H; Malmström P; Pettersson Skøld D; Søderberg M; Villman K; Bergh J;
Acta Oncol; 2011 Jan; 50(1):35-41. PubMed ID: 21174610
[TBL] [Abstract][Full Text] [Related]
4. Severe palmar-plantar erythema in a patient with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy.
Damasiewicz MJ; Chionh FJ; Hayes T
Intern Med J; 2007 Jul; 37(7):505-6. PubMed ID: 17547732
[No Abstract] [Full Text] [Related]
5. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer.
Puhalla S; Mrozek E; Young D; Ottman S; McVey A; Kendra K; Merriman NJ; Knapp M; Patel T; Thompson ME; Maher JF; Moore TD; Shapiro CL
J Clin Oncol; 2008 Apr; 26(10):1691-7. PubMed ID: 18316792
[TBL] [Abstract][Full Text] [Related]
6. Cognitive impairment with significant brain parenchymal volume loss following standard adjuvant chemotherapy in a patient with breast cancer.
Swayampakula AK; Alkhouri N; Haut MW; Abraham J
Clin Adv Hematol Oncol; 2007 Dec; 5(12):985-7; discussion 987-8. PubMed ID: 18277960
[No Abstract] [Full Text] [Related]
7. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
8. Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil).
Hatam N; Ahmadloo N; Ahmad Kia Daliri A; Bastani P; Askarian M
Arch Gynecol Obstet; 2011 Jul; 284(1):215-20. PubMed ID: 20740365
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
Fornier MN; Seidman AD; Theodoulou M; Moynahan ME; Currie V; Moasser M; Sklarin N; Gilewski T; D'Andrea G; Salvaggio R; Panageas KS; Norton L; Hudis C
Clin Cancer Res; 2001 Dec; 7(12):3934-41. PubMed ID: 11751485
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant docetaxel for node-positive breast cancer.
Martin M; Pienkowski T; Mackey J; Pawlicki M; Guastalla JP; Weaver C; Tomiak E; Al-Tweigeri T; Chap L; Juhos E; Guevin R; Howell A; Fornander T; Hainsworth J; Coleman R; Vinholes J; Modiano M; Pinter T; Tang SC; Colwell B; Prady C; Provencher L; Walde D; Rodriguez-Lescure A; Hugh J; Loret C; Rupin M; Blitz S; Jacobs P; Murawsky M; Riva A; Vogel C;
N Engl J Med; 2005 Jun; 352(22):2302-13. PubMed ID: 15930421
[TBL] [Abstract][Full Text] [Related]
11. Panmucositis and chemosensitisation associated with betel quid chewing during dose-dense adjuvant breast cancer chemotherapy.
Epstein RJ; Leung TW; Cheung PS
Cancer Chemother Pharmacol; 2006 Dec; 58(6):835-7. PubMed ID: 16532344
[TBL] [Abstract][Full Text] [Related]
12. Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients.
Magné N; Castadot P; Chargari C; Di Leo A; Philippson C; Van Houtte P
Radiother Oncol; 2009 Jan; 90(1):116-21. PubMed ID: 19013659
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel/Cyclophosphamide-induced ultraviolet recall dermatitis.
Basile FG; Creamer S
J Clin Oncol; 2011 Dec; 29(34):e840-1. PubMed ID: 22025156
[No Abstract] [Full Text] [Related]
14. A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer.
Yardley DA; Burris HA; Farley CP; Barton JH; Peacock NW; Spigel DR; Greco FA; Hainsworth JD
Clin Breast Cancer; 2008 Jun; 8(3):242-8. PubMed ID: 18650154
[TBL] [Abstract][Full Text] [Related]
15. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
16. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
[TBL] [Abstract][Full Text] [Related]
17. Therapy-related leukemia cutis after adjuvant chemotherapy in a breast cancer patient.
Lee HY; Ng HJ; Wong PC; Pang SM
Acta Derm Venereol; 2010 Nov; 90(6):649-50. PubMed ID: 21057758
[No Abstract] [Full Text] [Related]
18. Chemotherapy-induced acral erythema in a pediatric patient with acute monoblastic leukemia.
Demircioğlu F; Oren H; Yilmaz S; Arslansoyu S; Eren S; Irken G
Pediatr Hematol Oncol; 2008; 25(3):211-5. PubMed ID: 18432504
[TBL] [Abstract][Full Text] [Related]
19. Tumor shrinkage evaluation during and after preoperative doxorubicin and cyclophosphamide followed by docetaxel in patients with breast cancer.
Puglisi F; Mansutti M; Aprile G; Minisini AM; Di Loreto C; Bazzocchi M; Londero V; Cedolini C; Gentile G; Pizzolitto S; Piga A; Sobrero A
Anticancer Res; 2004; 24(4):2487-93. PubMed ID: 15330203
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide (ATC) for high-risk breast cancer is feasible in the community setting.
Burtness B; Windsor S; Holston B; DiStasio S; Staugaard-Hahn C; Abrantes J; Kneuper-Hall R; Farber L; Orell J; Bober-Sorcinelli K; Haffty BG; Reiss M
Cancer J Sci Am; 1999; 5(4):224-9. PubMed ID: 10439168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
